{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:32Z","timestamp":1789725932342,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["4-22-PDFPM-06"],"award-info":[{"award-number":["4-22-PDFPM-06"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["09150162310058"],"award-info":[{"award-number":["09150162310058"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010909","name":"Excellent Young Scientists Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"The Swedish Heart Lung Foundation","doi-asserted-by":"publisher","award":["20250416"],"award-info":[{"award-number":["20250416"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304245"],"award-info":[{"award-number":["82304245"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.06.041","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:02:35Z","timestamp":1784934155000},"page":"964-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-608X","authenticated-orcid":false,"given":"Yang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien C.H.M.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6498-0257","authenticated-orcid":false,"given":"Antoine","family":"Cr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-6825","authenticated-orcid":false,"given":"Edouard L.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.06.041_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.041_bib2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.06.041_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.kint.2020.08.036","article-title":"Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists","volume":"99","author":"Mann","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.041_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000529374","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2026.06.041_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2026.06.041_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2026.06.041_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.041_bib51","unstructured":"A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). ClinicalTrials.gov Identifier: NCT03819153. Updated March 20, 2025. Accessed August 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03819153"},{"key":"10.1016\/j.kint.2026.06.041_bib8","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2026.06.041_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","article-title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","volume":"101","author":"Xu","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.041_bib10","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0140-6736(95)90120-5","article-title":"Can overall results of clinical trials be applied to all patients?","volume":"345","author":"Rothwell","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.06.041_bib11","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M18-3668","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement: explanation and elaboration","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2026.06.041_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jrsssb\/qkac001","article-title":"Estimating heterogeneous treatment effects with right-censored data via causal survival forests","volume":"85","author":"Cui","year":"2023","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.kint.2026.06.041_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12944-024-02132-x","article-title":"Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Gong","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.kint.2026.06.041_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2026.06.041_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.kint.2026.06.041_bib52","unstructured":"The Stockholm CREAtinine Measurements Project (SCREAM). ClinicalTrials.gov Identifier: NCT06239129. Updated February 2, 2024. Accessed August 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06239129"},{"key":"10.1016\/j.kint.2026.06.041_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.kint.2026.06.041_bib17","first-page":"S246","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.kint.2026.06.041_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: an update","author":"Kazancio\u011flu","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.kint.2026.06.041_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ije\/dyaa213","article-title":"Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations","volume":"50","author":"Tennant","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.kint.2026.06.041_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.kint.2022.09.020","article-title":"Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations","volume":"103","author":"Carrero","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.041_bib21","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2026.06.041_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.06.041_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.kint.2026.06.041_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.122.062626","article-title":"Heterogeneity in the association between the presence of coronary artery calcium and cardiovascular events: a machine-learning approach in the MESA study","volume":"147","author":"Inoue","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.041_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12874-023-01974-w","article-title":"Performance metrics for models designed to predict treatment effect","volume":"23","author":"Maas","year":"2023","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.kint.2026.06.041_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300041","article-title":"Individualized treatment effect prediction with machine learning \u2014 salient considerations","volume":"3","author":"Desai","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.kint.2026.06.041_bib27","series-title":"Proceedings of the 31st International Conference on Neural Information Processing Systems","first-page":"4768","article-title":"A unified approach to interpreting model predictions","author":"Lundberg","year":"2017"},{"key":"10.1016\/j.kint.2026.06.041_bib28","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/sim.8672","article-title":"Sensitivity analysis of treatment effect to unmeasured confounding in observational studies with survival and competing risks outcomes","volume":"39","author":"Huang","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2026.06.041_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2026.06.041_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.kint.2026.06.041_bib31","first-page":"2075","article-title":"Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials","volume":"45","author":"Kent","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.kint.2026.06.041_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.06.041_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109114","article-title":"Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence","volume":"39","author":"D\u00e1vila-Garc\u00eda","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.kint.2026.06.041_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107866","article-title":"Sex differences in the weight response to GLP-1RA in people with type 2 diabetes: a long-term longitudinal real-world study","volume":"219","author":"Marassi","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2026.06.041_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","article-title":"Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety","volume":"24","author":"Tang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2026.06.041_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.36100","article-title":"Glucose-lowering medication classes and cardiovascular outcomes in patients with type 2 diabetes","volume":"8","author":"Neugebauer","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2026.06.041_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.041_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.06.041_bib39","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1681\/ASN.2021040498","article-title":"Large between-patient variability in eGFR decline before clinical trial enrollment and impact on atrasentan's efficacy: a post hoc analysis from the SONAR trial","volume":"32","author":"Waijer","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.06.041_bib53","unstructured":"Study Of Diabetic Nephropathy With Atrasentan (SONAR). ClinicalTrials.gov Identifier: NCT01858532. Updated April 24, 2019. Accessed August 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01858532"},{"key":"10.1016\/j.kint.2026.06.041_bib40","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.ekir.2025.04.042","article-title":"Pre-treatment GFR slopes predict dapagliflozin response in IgA nephropathy","volume":"10","author":"Ueda","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.06.041_bib41","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.06.041_bib54","unstructured":"A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes. ClinicalTrials.gov Identifier: NCT02017171. Updated December 4, 2020. Accessed August 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02017171"},{"key":"10.1016\/j.kint.2026.06.041_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.0000000000000272","article-title":"Heterogeneous treatment effects of intensive glycemic control on kidney microvascular outcomes and mortality in ACCORD","volume":"35","author":"Charu","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.06.041_bib55","unstructured":"Action to Control Cardiovascular Risk in Diabetes (ACCORD). ClinicalTrials.gov Identifier: NCT00000620. Updated November 22, 2016. Accessed August 7, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00000620"},{"key":"10.1016\/j.kint.2026.06.041_bib43","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1513\/AnnalsATS.202309-836OC","article-title":"Glucagon-like peptide 1 receptor agonists and asthma exacerbations: which patients benefit most?","volume":"21","author":"Wang","year":"2024","journal-title":"Annals Am Thorac Soc"},{"key":"10.1016\/j.kint.2026.06.041_bib44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/sim.10059","article-title":"Do machine learning methods lead to similar individualized treatment rules? a comparison study on real data","volume":"43","author":"Bouvier","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2026.06.041_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103697","article-title":"Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment effect in acute respiratory distress syndrome: a secondary analysis of three randomised controlled trials","volume":"74","author":"Sinha","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2026.06.041_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.22390","article-title":"Predictive modeling of heterogeneous treatment effects in RCTs: a scoping review","volume":"8","author":"Selby","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.kint.2026.06.041_bib47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study","volume":"172","author":"St\u00fcrmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.kint.2026.06.041_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin Trials (London, England)"},{"key":"10.1016\/j.kint.2026.06.041_bib49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1532-5415.2010.02767.x","article-title":"Competing risk of death: an important consideration in studies of older adults","volume":"58","author":"Berry","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.kint.2026.06.041_bib50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1681\/ASN.0000000000000050","article-title":"The Kidney Failure Risk Equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts","volume":"34","author":"Grams","year":"2023","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:30:13Z","timestamp":1789723813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826006125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826006125"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.041","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}